Linperlisib - Shanghai Yingli Pharmaceutical
Alternative Names: HRS-3536; Intarel; YY-20394Latest Information Update: 14 Dec 2023
At a glance
- Originator Shanghai Yingli Pharmaceutical
- Developer Jiangsu Hengrui Medicine Co.; Shanghai Yingli Pharmaceutical
- Class Antineoplastics; Morpholines; Piperidines; Pyridines; Quinazolines; Small molecules; Sulfonamides
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Follicular lymphoma
- Phase III Peripheral T-cell lymphoma
- Phase II Chronic lymphocytic leukaemia
- Phase I/II Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Phase I Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 10 Dec 2023 Efficacy and adverse events data from a phase II trial in Peripheral T-cell lymphoma released by Shanghai Yingli Pharmaceutical
- 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Updated adverse events and efficacy data from a phase I/II trial in diffuse large B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)